These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
353 related articles for article (PubMed ID: 10852644)
1. Lipid-lowering treatment in coronary artery disease: how low should cholesterol go? Jones PH Drugs; 2000 May; 59(5):1127-35. PubMed ID: 10852644 [TBL] [Abstract][Full Text] [Related]
2. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments. Evans M; Roberts A; Davies S; Rees A Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326 [TBL] [Abstract][Full Text] [Related]
3. Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy. Isles CG; Paterson JR QJM; 2000 Sep; 93(9):567-74. PubMed ID: 10984551 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic efficacy of the lipid-lowering armamentarium: the clinical benefits of aggressive lipid-lowering therapy. Hunninghake DB Am J Med; 1998 Feb; 104(2A):9S-13S. PubMed ID: 9550501 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-analysis. Sabatine MS; Wiviott SD; Im K; Murphy SA; Giugliano RP JAMA Cardiol; 2018 Sep; 3(9):823-828. PubMed ID: 30073316 [TBL] [Abstract][Full Text] [Related]
6. An evidence-based assessment of the NCEP Adult Treatment Panel II guidelines. National Cholesterol Education Program. Ansell BJ; Watson KE; Fogelman AM JAMA; 1999 Dec; 282(21):2051-7. PubMed ID: 10591388 [TBL] [Abstract][Full Text] [Related]
7. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study. Strandberg TE; Feely J; Sigurdsson EL; Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694 [TBL] [Abstract][Full Text] [Related]
8. Relationship between LDL-C and non-HDL-C levels and clinical outcome in the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Athyros VG; Mikhailidis DP; Papageorgiou AA; Symeonidis AN; Daskalopoulou SS; Kakafika AI; Pehlivanidis AN; Bouloukos VI; Langer A; Curr Med Res Opin; 2004 Sep; 20(9):1385-92. PubMed ID: 15383187 [TBL] [Abstract][Full Text] [Related]
9. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin. Breuer HW Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448 [TBL] [Abstract][Full Text] [Related]
10. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia. Malhotra HS; Goa KL Drugs; 2001; 61(12):1835-81. PubMed ID: 11693468 [TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain. Plans-Rubió P Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391 [TBL] [Abstract][Full Text] [Related]
12. Lipid-lowering medication for secondary prevention of coronary heart disease in a German outpatient population: the gap between treatment guidelines and real life treatment patterns. Ruof J; Klein G; März W; Wollschläger H; Neiss A; Wehling M Prev Med; 2002 Jul; 35(1):48-53. PubMed ID: 12079440 [TBL] [Abstract][Full Text] [Related]
13. [Statins in primary prevention of coronary heart disease]. Paulweber B Wien Med Wochenschr; 1999; 149(5-6):129-38. PubMed ID: 10408004 [TBL] [Abstract][Full Text] [Related]
15. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome. Nesto RW Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526 [TBL] [Abstract][Full Text] [Related]
16. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial. Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317 [TBL] [Abstract][Full Text] [Related]
17. Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks. McKenney JM Am J Cardiol; 2005 Aug; 96(4A):60E-66E. PubMed ID: 16098846 [TBL] [Abstract][Full Text] [Related]
18. Cerivastatin: a review of its pharmacological properties and therapeutic efficacy in the management of hypercholesterolaemia. Plosker GL; Dunn CI; Figgitt DP Drugs; 2000 Nov; 60(5):1179-206. PubMed ID: 11129127 [TBL] [Abstract][Full Text] [Related]
19. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57). Desai NR; Giugliano RP; Zhou J; Kohli P; Somaratne R; Hoffman E; Liu T; Scott R; Wasserman SM; Sabatine MS J Am Coll Cardiol; 2014 Feb; 63(5):430-3. PubMed ID: 24161333 [TBL] [Abstract][Full Text] [Related]